These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 10624549)

  • 1. The preventative role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia.
    Sachdev P; Saharov T; Cathcart S
    Biol Psychiatry; 1999 Dec; 46(12):1672-81. PubMed ID: 10624549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia.
    Singh A; Naidu PS; Kulkarni SK
    Eur J Pharmacol; 2003 Sep; 477(2):87-94. PubMed ID: 14519411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms.
    Naidu PS; Singh A; Kulkarni SK
    Br J Pharmacol; 2002 May; 136(2):193-200. PubMed ID: 12010767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extract of Ginkgo biloba is equivalent to vitamin E in attenuating and preventing vacuous chewing movements in a rat model of tardive dyskinesia.
    An HM; Tan YL; Shi J; Wang ZR; Li J; Wang YC; Kosten TR; Zhou DF; Yang FD; Zhang XY
    Behav Pharmacol; 2013 Oct; 24(7):610-6. PubMed ID: 23994817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements.
    Naidu PS; Kulkarni SK
    Eur J Pharmacol; 2001 Sep; 428(1):81-6. PubMed ID: 11779040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central administration of the neurotensin receptor antagonist SR48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia.
    McCormick SE; Stoessl AJ
    Neuroscience; 2003; 119(2):547-55. PubMed ID: 12770567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of subthalamic nucleus lesions in a putative model of tardive dyskinesia in the rat.
    Stoessl AJ; Rajakumar N
    Synapse; 1996 Nov; 24(3):256-61. PubMed ID: 8923666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ginkgo biloba and vitamin E ameliorate haloperidol-induced vacuous chewingmovement and brain-derived neurotrophic factor expression in a rat tardive dyskinesia model.
    Shi J; Tan YL; Wang ZR; An HM; Li J; Wang YC; Lv MH; Yan SX; Wu JQ; Soares JC; Yang FD; Zhang XY
    Pharmacol Biochem Behav; 2016 Sep; 148():53-8. PubMed ID: 27264436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia.
    Stoessl AJ; Polanski E; Frydryszak H
    Mov Disord; 1993 Oct; 8(4):445-52. PubMed ID: 7901759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroleptic-induced striatal damage in rats: a study of antioxidant treatment using accelerometric and immunocytochemical methods.
    Lohr JB; Caligiuri MP; Manley MS; Browning JA
    Psychopharmacology (Berl); 2000 Feb; 148(2):171-9. PubMed ID: 10663432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidative mechanisms and tardive dyskinesia.
    Lohr JB; Kuczenski R; Niculescu AB
    CNS Drugs; 2003; 17(1):47-62. PubMed ID: 12467492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D(1A) receptor function in a rodent model of tardive dyskinesia.
    Van Kampen JM; Stoessl AJ
    Neuroscience; 2000; 101(3):629-35. PubMed ID: 11113312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Fundam Clin Pharmacol; 2007 Oct; 21(5):521-9. PubMed ID: 17868205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1130-8. PubMed ID: 17513028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. U-74500A (lazaroid), a 21-aminosteroid attenuates neuroleptic-induced orofacial dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Methods Find Exp Clin Pharmacol; 2007 Nov; 29(9):601-5. PubMed ID: 18193111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Withania somnifera glycowithanolides on a rat model of tardive dyskinesia.
    Bhattacharya SK; Bhattacharya D; Sairam K; Ghosal S
    Phytomedicine; 2002 Mar; 9(2):167-70. PubMed ID: 11995951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT3 receptor antagonists.
    Naidu PS; Kulkarni SK
    Eur J Pharmacol; 2001 May; 420(2-3):113-7. PubMed ID: 11408032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):451-61. PubMed ID: 17988775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of neurotensin in a rodent model of tardive dyskinesia.
    Stoessl AJ
    Neuropharmacology; 1995 Apr; 34(4):457-62. PubMed ID: 7566478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.